ENTER


Полный размерЗакрыть
Details


Zavhorodnia N.H.1, 2, Bezdenezhna O.O.1, 2, Bezdenezhnyi S.V.2
1SI «Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine», Zaporizhia, Ukraine
2Clinic of Modern Ophthalmology «Visus», Zaporizhia, Ukraine


SUMMARY

Objective. To evaluate the efficiency of 0.005 % latanoprost / 0.5 % timolol maleate fixed combinations, compared with 1 % brinzolamide / 0.5 % timolol maleate in patients with primary open-angle glaucoma (POAG).

Methods. In this study 50 eyes of 30 patients with POAG were examined. Fifteen patients (25 eyes) were appointed instillation by 1 % brinzolamide / 0.5 % timolol maleate (AZARGA, Alcon) within 1 month, then without a break in the treatment they were switched to 0.005 % latanoprost / 0.5 % timolol maleate (LANOTAN-T, Farmak) also for 1 month. Patients of the second group opposite at the beginning of treatment were appointed instillation by 0.005 % latanoprost / 0.5 % timolol maleate, and after 1 month were switched to the instillation of 1 % brinzolamide / 0.5 % timolol maleate.

Complex examination in addition to general ophthalmological methods included computer static perimetry and computer sphygmography.

Results. The appointment of a fixed combinations of 0.005 % latanoprost / 0.5 % timolol maleate and 1 % brinzolamide / 0.5 % timolol maleate provides a clinically significant decrease in intraocular presure from baseline level by 31 and 32 %, respectively.

It has been found that the combination of 0.005 % latanoprost / 0.5 % timolol maleate has more expressed neuroprotective effects compared with 1 % brinzolamide / 0.5 % timolol maleate due to improvement of microcirculation.

Keywords: primary open-angle glaucoma, fixed combinations of antihypertensive drugs.

 


REFERENCES
1. Quigley H. A., Broman А. Т. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006; (90): 262–267.
2. Vesnina N. A., Kudinova-Savchenko N. A., Saar T. A. Prostaglandins in treatment of glaucoma neiroopticopaty. Suchasni medichni tehnologiyi [Modern medical technology]. 2012; (2): 44–45 (in Russian).
3. Kass M. A., Heuer D. K., Higginbotham E. J., Johnson C. A., Keltner J. L., Miller J. P., Parrish R. K. 2nd, Wilson M. R., Gordon M. O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; (120): 701–713.
4. Fogagnolo P., Rossetti L. Medical treatment of glaucoma: Present and future. Expert Opinion on Investigational Drugs. 2011; (20): 947–959.
5. Rasmussen C. A., Kaufman P. L. Novel therapeutic approaches for glaucoma. Drugs of the Future. 2011; (36): 287–300.
6. Barbón-García J. J., Alvarez-Suárez M. L. Paracentesis and ocular massage as treatment of central retinal artery occlusion. Archivos de la Sociedad Española de Oftalmología. 2007; (82): 657–659.
7. Zavhorodnia N. H., Bezdenezhna O. O., Bezdenezhnyi S. V. Immediate and long-term results of treatment of chronic ischemic optic neuropathy with local application of antihypertensive therapy. Oftalmologicheskiy zhurnal [Journal of Ophthalmology]. 2012; (2): 26–30.

05.08.2015